BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAWS: ETIOLOGY, RISK FACTORS, DIAGNOSTIC CRITERIA, TREATMENT ALTERNATIVES

Öz

Bisphosphonates are synthetic analogues of pyrophosphates used for the treatment of hypercalcemia in patients with malignancies and bone metastasis and for the treatment of multiple myeloma, bone resorption in the case of metastatic malignant diseases, and in the treatment of osteoporosis. Even though their application has shown to be effective in reducing pain and minimizing the risk of skeletalrelated events, their administration may also bring adverse events such as osteonecrosis of the jaws. Since the end of 2003, several reports have been published on jaw osteonecrosis possibly being associated with the administration of bisphosphonates. The aim of the present review was to analyze the etiology, clinical manifestations, risk factors, radiologic features and different treatment strategies of bisphosphonate-associated osteonecrosis of the jaws.

Anahtar Kelimeler

• Bisphosphonate
• Osteonecrosis
• Alveolar bone

BİSFOSFANAT KULLANIMINA BAĞLI ÇENE KEMİĞİNDE GELİŞEN OSTEONEKROZ: ETYOLOJİ, RİSK FAKTÖRLERİ, TANI KRİTERLERİ VE TEDAVİ ALTERNATİFLERİ

Öz

Bisfosfanatlar pirofosfatların sentetik analogları olup; malignensilere bağlı olarak gelişen hiperkalsemi, multipl myeloma, kemik metastazı tedavisin yanında osteoporöz tedavisi için kullanılan ilaçlardır. İlacın uygulanması iskeletsel anomalilere bağlı olarak gelişen riskleri minimuma indirerek ağrı kontrolünü sağlasa da, ilacın kullanımına bağlı olarak çene kemiklerinde gelişen osteonekroz gibi yan etkileri de görülebilmektedir. 2003 yılının sonlarından itibaren, bu konuda bildirilen olgu sayısı hızla artış göstermiştir. Bu derlemenin amacı bisfosfanat kullanıma bağlı olarak çene kemiklerinde gelişen osteonekroz olgularının etiyolojisini, klinik ve radyolojik bulgularını, risk faktörlerini ve farklı tedavi seçeneklerini irdelemektir

Anahtar Kelimeler

• Bisfosfanat
• Osteonekroz
• Alveol kemiği

Kaynakça

1. Font RF, Garcia ML, Martinez JMO. Osteochemonecrosis of the Jaws due to Bisphosphonate treatments: Update. Med Oral Patol Oral Cir Bucal 2008; 13: 318-24.
2. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-4.
3. Crépin S, Laroche ML, Sarry B, Merle L. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. Eur J Clin Pharmacol 2010; 66: 547-54.
4. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006; 77: 109-17. with
5. Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, Paula LM, Paula AP, Guerra EN. Bisphosphonateassociated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 14-21.
6. Katz H. Endodontic Implications of Biphosphonate- Associated Osteonecrosis of the Jaws: A Report of Three Cases. J Endod 2005; 31: 831-34. 7. Sparidans RW, Twiss Bisphosphonates in bone diseases. Pharm World Sci 1998; 20: 206–13. IM, Talbot S.
7. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003;1: 45–52.
8. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004; 4: 711–19.

9. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17: 137-44.
10. Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The effects od bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 5-13.
11. Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int 2004;15: 792-8.
12. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular bisphosphonates: Current status. Clin Cancer Res 2006; 12: 62225-305. of action of
13. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-58.
14. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget's disease of bone: indication for treatment and review of current therapies. J Bone Miner Res 2006; 21(Suppl 2): 94-8.
15. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007; 22: 142-8.
16. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009 15; 115: 1631-7.
17. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W. Prevalence and risk factors of bisphosphonate- associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008; 54: 1066-72.
18. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 2006; 137:1144–50.
19. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363: 1377-85.
20. Kamoun-Goldrat A, Ginisty D, Merrer M. Effect of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008; 116: 195-8. 22. Reid IR, Bolland MJ, Grey AB. Is bisphosphonateassociated osteonecrosis of the jaw caused by soft tissuetoxicity? Bone 2007; 41: 318- 20.
21. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S,Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of Oral Mucosal Cell Wound Healing by Bisphosphonates. J Oral Maxillofac Surg 2008; 66: 839-47.
22. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
23. Ruggiero SL, Mehrotra B, Rosenberg T, Engroff, SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34.
24. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol 2005; 34: 120-3.
25. Carneiro E, Vibhute P, Montazem A, Som PM. Bisphosphonate-associated osteonecrosis. AJNR Am J Neuroradiol 2006; 27: 1096-7. mandibular
26. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review. Laryngoscope 2007;117: 30- 4.
27. Friedrich RE, Blake FA. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients. Anticancer Res 2007; 27: 1841-5.
28. Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonate- associated osteonecrosis of the jaws. Head Neck. 2009; 31: 202-6.
29. Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente bisphosphonate-associated osteonecrosis of the experiences with
30. tedavi yaklaşımları. ADO Klinik Bilimler Dergisi 2007; 1: 37- 42.
31. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency osteonecrosis of the jaws in Australia. J Oral Maxillofac 2007; 65: 415-23.
32. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-102.
33. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P: Jaw bone necrosis without previous dental extractions associated with bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005; 34: 613- 761. 44. Ruggiero the use of SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433–41.
34. Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134: 620–3.
35. Marx RE, Sawatari Y, Fortin M, Braumand V. -induced (Osteonecrosis /osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of Oral Maxillofacial Surgery 2005: 63; 1567-75. exposed bone
36. Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws - clinicopathologic and radiologic characteristics, therapeuticstrategies. 2010;186: 367–73. preventive Strahlenther Onkol
37. Ergün S, Güneri P, Koca H. Çene kemiklerinin yeni tehlikesi: bisfosfonatlar. Cumhuriyet Üniversitesi Diş Hekimliği Fakültesi Dergisi 2008; 11: 140-5.
38. Soydan SS, Veziroğlu Şenel F, Araz K. Bifosfonata bağlı osteonekrozun patogenezi ve tedavisi. Hacettepe Diş Hekimliği Fakültesi Dergisi 2009; 33: 61-8.
39. Khan AA, Sándor GKB, Dore E, Morrison AD, Alsahli M, Amin F, et al. Canadian consensus practice guidelines osteonecrosis of the jaw. J Rheumatol 2008; 35: 1391–7. associated
40. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga G, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 2007; 12: E336–40.
41. Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, et al. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol 2009; 71: 12–21.
42. British Dental Association. Bisphosphonates fact file. London: British Dental Association; 2008. URL: http://www.bda.org.
43. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-76.
44. bisphosphonate-related
45. Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position osteonecrosis of the jaws—2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 2009; 67: 2698–9.
46. Bisphosphonaterelated
47. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2010; 14: 311-7.
48. Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl TJ, Mack MG. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 2008; 63: 71–7.
49. Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonate- associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 358–64.
50. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med 2009; 50: 30-5.
51. Elad S, Gomori MJ, Ben-Ami N, Friedlander- Barenboim S, Regev E, Lazarovici TS, Yarom N. Bisphosphonate-related osteonecrosis of the jaw: clinical correlations with computerized tomography presentation. Clin Oral Investig 2010; 14: 43-50.
52. Chiandussi S, Biasotto M, Dore F, et al. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006; 35: 236–43.
53. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104: 249-58.
54. Barragan-Adjemian C, Lausten L, Ang DB, Johnson M, Katz J, Bonewald LF.Bisphosphonate-related osteonecrosis of the jaw: model and diagnosis with cone beam computerized tomography. Cells Tissues Organs 2009; 189: 284-8.
55. Singer SR, Mupparapu M. Plain film and CBCT findings in a case of bisphosphonate-related osteonecrosis of the jaw. Quintessence Int 2009; 40: 163-5.
56. Hino S, Murase R, Terakado N, et al. Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: scintigraphy. Int J Oral Maxillofac Surg 2005; 34: 576–78. study by 99mTc
57. van der Waal RI, Buter J, van der Waal I. Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg 2003; 41: 3–6. 67. Studer G, Gratz KW, Glanzmann C. Osteoradionecrosis of the mandibula in patients treated with different fractionations. Strahlenther Onkol 2004; 180: 233–40.
58. Studer G, Studer SP, Zwahlen RA, et al. Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2006; 182: 283–8.
59. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-8.
60. Treister NS, Friedland B, Woo SB. Use of cone- beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:753-64.
61. Schulze D, Blessmann M, Pohlenz P, Wagner KW, Heiland M.Diagnostic criteria for the detection of mandibular computed tomography. Dentomaxillofac Radiol 2006; 35: 232-5. using cone-beam
62. Kumar V, Pass B, Guttenberg SA, Ludlow J, Emery RW, Tyndall DA, et al. Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity. J Am Dent Assoc 2007; 138: 602-9.
63. Fullmer JM, Scarfe WC, Kushner GM, Alpert B, Farman AG. Cone beam computed tomographic findings in refractory chronic suppurative osteomyelitis of the mandible. Br J Oral Maxillofac Surg 2007; 45: 364-71.
64. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis- Papaiakovou E, Christoulas D, Terpos E, Bamias A. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117-20.
65. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20: 137-45.
66. Rosen HN, Moses AC, Garber J et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of a low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000; 66: 100.
67. Yarom N, Lazarovici TS, Elad S. Oral bisphosphonate-related osteonecrosis of the jaw: incidence, clinical features, prevention, and treatment recommendations. Clinic Rev Bone Miner Metab 2010: 8; 27–31.
68. Bone HG, Hosking D, Devogelaer JP et al. Ten years’ osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189. alendronate for
69. Bagan JV, Jimenez Y, Murillo J et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases (Letter). Oral Oncol 2006; 42: 327.
70. Carlson EC. The role of surgical resection in the management osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67.
71. bisphosphonate-related
72. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonates induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397.
73. Kademani D, Koka S, Lacy MQ, Rajkumar V. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006; 81: 1100.
74. Freiberger JJ. The utility of hyperbaric oxygen in of the osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67(5 Suppl.):96–106.
75. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al. Hyperbaric oxygen treatment osteonecrosis of the jaw; a case series. J Oral Maxillofac Surg 2007; 65: 1321–7.
76. Lee CY, David T, Nishime M. Use of platelet-rich plasma bisphosphonate-associated osteonecrosis of the jaw: a report of two cases. J Oral Implantol 2007; 33: 371-382. of oral
77. Harper RP, Fung E. Resolution of bisphosphonate- associated osteonecrosis of the mandible: possible application for intermittent low dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007; 65: 573–80.
78. Curi MM, Cossolin GSI, Koga DH, Araşjo SR, Feher O, dos Santos MO, et al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet- rich plasma: report of 3 cases. J Oral Maxillofac Surg 2007; 65: 349–55.
79. Vescovi P, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M. Nd:YAG laser biostimulation necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 2007;45: 628– 32.
80. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 2007; 18: 1071–5.
81. Stübinger S, Dissmann JP, Pinho NC, Saldamli B, Seitz O, Sader R. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation. Lasers Surg Med 2009; 41: 26–30.
82. McLeod NM, Patel V, Kusanale A, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. Br J Oral Maxillofac Surg 2011; 49: 335-42.
83. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18: 1363-70.